Voluntis (Euronext Paris, Ticker: VTX – ISIN: FR0004183960), a leader in digital therapeutics, will announce its business review and results for the first half of 2019 on Thursday 19 September 2019 at 8:00 am CEST.
The Company’s management will host a conference call with presentation and Q&A at 3:30pm CEST. The call will be conducted in English and a replay will be available for 90 days via the call number below.
To access the conference call, please dial one of the appropriate numbers below quoting the code:
France: +33 1 70 71 01 59
International: +44 20 71 94 37 59
To access the presentation, which will be available a few minutes before the start of the conference call, please use the following link: Presentation
To replay the conference:
France: +33 (0)1 70 71 01 60
International: +44 20 33 64 51 47
Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self- manage their treatment every day, thus improving real-world outcomes. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to the patient and the care team so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. These real- time recommendations are based on digitized clinical algorithms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in diabetes and oncology. Voluntis has long-standing partnerships with leading life science companies. Based out of Boston and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance. For more information, please visit: http://www.www.voluntis.com
Voluntis is traded on the Euronext Paris – Compartment C market
Ticker: VTX – ISIN: FR0004183960